Experimental BTK inhibitor SAR442168 can significantly reduce disease activity with multiple sclerosis
-
Last Update: 2020-05-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Multiple sclerosis (MS) is a demyelinated neuropathy in which the insulating substance (i.emyelin) on the surface of nerve cells in the brain or spinal cord is damaged and the signal transduction of the nervous system is impaired, affecting the patient's activity, mind, and even mental stateSanofi announced today that in a Phase IIb clinical trial, the experimental BTK inhibitor SAR442168 for the treatment of recurrent multiple sclerosis (MS) reduced high-intensity lesions by 85%The company reported in February that the small molecule selective BTK inhibitor SAR442168 reached the main end of the trial, significantly reducing MS-related disease activity"We believe that brain permeability BTK inhibitors have the promise of reducing neuroinflammation and neurodegeneration," said John Reed, head of global research and development at sanofie,As we move forward, we will explore whether brain permeability BTK inhibitors have strong efficacy and excellent safety for patients with recurrent MSWe are launching four key Phase III clinical trials."the purpose of this Phase IIb study was to measure the number of brain lesions through MRI and to assess the dose-response relationship after 12 weeks of treatment at doses of SAR442168 at doses ranging from 5 mg to 60 mg
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
